Wall Street sell-side research analysts covering Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $15.7 on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $35 while the most conservative estimate stand at $9.
Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover Valeant Pharmaceuticals International, Inc.. They give the company shares an ABR of 3.2. This is based on the 10 analysts taken into consideration by Zacks.
Earnings Estimates for Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
Currently, Wall Street is projecting that the firm will post $0.95 earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on 2017-03-31, Valeant Pharmaceuticals International, Inc.'s EPS was reported as $2.8. This created a “surprise factor” 191.67% due to being $1.84 apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.
Investors will mark their calendars for 2017-08-08, the date when Valeant Pharmaceuticals International, Inc. (NYSE:VRX) are expected to release their quarterly results.
For the current quarter, analysts are expecting Bed Bath & Beyond Inc. (NASDAQ:BBBY) to report EPS of $0.65. This consensus estimate is provided by Zacks Research. After the period that ended on 2017-02-28, Bed Bath & Beyond Inc. (NASDAQ:BBBY) reported an EPS actual of $1.84. The difference between the actual and estimate resulted in a surprise factor of 3.95%. The company is expected to release their next earnings report on or around 2017-06-28. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.
Shares of Bed Bath & Beyond Inc. (NASDAQ:BBBY) have a current ABR or average broker rating of 3.29. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.
Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Bed Bath & Beyond Inc. (NASDAQ:BBBY) is $39.615. The top analyst target is $45, and the lowest target is $33 on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.